Randomised prospective multicentre trial on the effect of early enteral nutrition on gut barrier permeability in severe acute pancreatitis

	[X] Prospectively registered
Stopped	☐ Protocol
Overall study status	Statistical analysis plan
Stopped	☐ Results
Condition category	Individual participant data
Digestive System	Record updated in last year
	Stopped Condition category

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr Hemant Kocher

Contact details

Department of Health National Clinician Scientist
Senior Lecturer
Tumour Biology Laboratory
Cancer Research UK Clinical Centre
Queen Mary's School Of Medicine & Dentistry at Barts & The London
John Vane Science Centre
Charterhouse Square
London
United Kingdom
EC1M 6BQ

Additional identifiers

Protocol serial number PANC/EN/2005/v1

Study information

Scientific Title

Randomised prospective multicentre trial on the effect of early enteral nutrition on gut barrier permeability in severe acute pancreatitis

Acronym

PANCREAS 2000 ENSAP

Study objectives

Null hypothesis: Early enteral nutrition in patients suffering from severe acute pancreatitis does not ameliorate the increased gut permeability associated with disease.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Severe acute pancreatitis

Interventions

Group one: Enteral nutrition via nasogastric/nasojejunal tube, or sip feed, composition as stratified for each centre. To start immediately after randomisation.

Group two: 'Standard' fluid replacement, oral or via intravenous line, composition as stratified for each centre.

Updated 23/04/2015: the trial did not start due to lack of funding.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Reduction of proportion of patients with increased gut permeatbility from 80% by half to 40%.

Key secondary outcome(s))

- 1. Reduction in persistent organ failure (3 days) from 35% to 15%
- 2. Complications (with specific emphasis on infective complications).
- 3. Length of hospital/ICU stay

- 4. Return of normal GI function
- 5. Markers of intestinal ischaemia (Intestinal fatty acid binding protein) and other markers of gut permeability (endocAb), immune/inflammatory response

Completion date

30/04/2007

Reason abandoned (if study stopped)

Lack of funding/sponsorship

Eligibility

Key inclusion criteria

Patients aged 18 or over with a proven diagnosis of acute pancreatitis (pain and raised enzymes or computed tomography [CT] evidence) together with systemic inflammatory response syndrome (SIRS) or organ failure (Marshall score 2 or more for any organ system except liver, or Atlanta criteria) present for 24 hours or more, and within 72 hours of onset of symptoms.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/05/2005

Date of final enrolment

30/04/2007

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Queen Mary's School Of Medicine & Dentistry at Barts & The London
London
United Kingdom
EC1M 6BQ

Sponsor information

Organisation

Barts and the London NHS Trust (UK)

ROR

https://ror.org/00b31g692

Funder(s)

Funder type

Government

Funder Name

Barts and the London NHS Trust (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration